Nasdaq Grants Revelation Biosciences Inc. Continued Listing
2025年1月6日 - 8:00PM
ビジネスワイヤ（英語）
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or
“Revelation”), a clinical-stage life sciences company that is
focused on harnessing the power of trained immunity for the
treatment of disease, announced today that the Nasdaq Hearings
Panel issued a decision letter granting Revelation’s request to
continue its listing on The Nasdaq Stock Market, subject to its
stock trading at or above $1.00 for at least ten consecutive
trading days by February 14, 2025.
Additionally, the Nasdaq Hearings Panel confirmed that the
Company has regained compliance with the Equity Requirement of
Listing Rule 5550(b)(1) for which the Company was issued a notice
of delisting for failure to comply with Equity Requirement of
Listing Rule 5550(b)(1) on August 14, 2024.
“We are very thankful to the Nasdaq Hearings Panel for
recognizing the significant progress made following the tumultuous
time for the Company post SPAC merger,” said James Rolke, Chief
Executive Officer of Revelation. “Now that our obligations from the
SPAC merger have settled, we can focus on the development of Gemini
and we look forward to the initiation of our Phase 1b clinical
study in chronic kidney patients shortly.”
On December 3, 2024, the Company announced the successful
exercise of warrants for $4 million. On December 2, 2024,
Revelation announced FDA acceptance of the Gemini IND. The Company
expects to initiate its Phase 1b clinical study in the first half
of 2025. Previously the Company reached a milestone with
successfully completing the GMP manufacture of the Gemini drug
product to support clinical trials.
For more information on Revelation, please visit
www.RevBiosciences.com.
About Gemini
Gemini is an intravenously administrated, proprietary
formulation of phosphorylated hexaacyl disaccharide (PHAD®) that
reduces the damage associated with inflammation by reprograming the
innate immune system to respond to stress (trauma, infection, etc.)
in an attenuated manner. Revelation has conducted multiple
preclinical studies demonstrating the therapeutic potential of
Gemini in the target indications. Earlier this year Revelation
announced positive Phase 1 clinical data for intravenous treatment
with Gemini. The primary safety endpoint was met in the Phase 1
study, and results demonstrated statistically significant
pharmacodynamic activity as observed through expected changes in
multiple biomarkers including upregulation of IL-10.
Gemini is being developed for multiple indications including as
a pretreatment to prevent or reduce the severity and duration of
acute kidney injury (GEMINI-AKI program), and as pretreatment to
prevent or reduce the severity and duration of post-surgical
infection (GEMINI-PSI program). In addition, Gemini may be a
treatment to stop or slow the progression of chronic kidney disease
(GEMINI-CKD program).
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences
company focused on harnessing the power of trained immunity for the
prevention and treatment of disease using its proprietary
formulation Gemini. Revelation has multiple ongoing programs to
evaluate Gemini, including as a prevention for post-surgical
infection, as a prevention for acute kidney injury, and for the
treatment of chronic kidney disease.
For more information on Revelation, please visit
www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These forward-looking statements are generally
identified by the words "anticipate", "believe", "expect",
"estimate", "plan", "outlook", and "project" and other similar
expressions. We caution investors that forward-looking statements
are based on management’s expectations and are only predictions or
statements of current expectations and involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those anticipated by the
forward-looking statements. Revelation cautions readers not to
place undue reliance on any such forward looking statements, which
speak only as of the date they were made. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: the ability of
Revelation to meet its financial and strategic goals, due to, among
other things, competition; the ability of Revelation to grow and
manage growth profitability and retain its key employees; the
possibility that the Revelation may be adversely affected by other
economic, business, and/or competitive factors; risks relating to
the successful development of Revelation’s product candidates; the
ability to successfully complete planned clinical studies of its
product candidates; the risk that we may not fully enroll our
clinical studies or enrollment will take longer than expected;
risks relating to the occurrence of adverse safety events and/or
unexpected concerns that may arise from data or analysis from our
clinical studies; changes in applicable laws or regulations;
expected initiation of the clinical studies, the timing of clinical
data; the outcome of the clinical data, including whether the
results of such study is positive or whether it can be replicated;
the outcome of data collected, including whether the results of
such data and/or correlation can be replicated; the timing, costs,
conduct and outcome of our other clinical studies; the anticipated
treatment of future clinical data by the FDA, the EMA or other
regulatory authorities, including whether such data will be
sufficient for approval; the success of future development
activities for its product candidates; potential indications for
which product candidates may be developed; the ability of
Revelation to maintain the listing of its securities on NASDAQ; the
expected duration over which Revelation’s balances will fund its
operations; and other risks and uncertainties described herein, as
well as those risks and uncertainties discussed from time to time
in other reports and other public filings with the SEC by
Revelation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250106814892/en/
Company Contacts
Mike Porter Investor Relations Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III Chief Financial Officer Revelation
Biosciences Inc. Email: czygmont@revbiosciences.com
Revelation Biosciences (NASDAQ:REVB)
過去 株価チャート
から 12 2024 まで 1 2025
Revelation Biosciences (NASDAQ:REVB)
過去 株価チャート
から 1 2024 まで 1 2025
